Neuropathic Pain | Unmet Need | Detailed Expanded Analysis Postherpetic Neuralgia

Publish date: April 2016

Login to access report

Postherpetic neuralgia (PHN) has served—and continues to serve—as a gateway indication into the lucrative neuropathic pain (NP) therapy market. Drugs such as Pfizer’s Lyrica (pregabalin), gabapentin (Pfizer’s Neurontin, generics), and the 5% lidocaine patch (Endo/Grünenthal’s Lidoderm/Versatis, generics) all capitalized on their approvals for PHN in the United States and Europe to achieve wider commercial success in the treatment of other forms of NP, such as neuropathic back pain and postsurgical/post-trauma NP. Despite the availability of multiple generic analgesics and well-established treatments for PHN, the substantial percentage of patients refractory to treatment, the high rate of polypharmacy, and the large unmet need associated with pain treatment make PHN—and NP overall—an area of commercial opportunity.

Table of contents

  • Detailed Expanded Analysis Postherpetic Neuralgia
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Postherpetic Neuralgia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Non-Clinical Factors
      • Stated Versus Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Non-Clinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Postherpetic Neuralgia
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Non-Clinical Factors
      • Unmet Need in Postherpetic Neuralgia and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Postherpetic Neuralgia Market and Emerging Therapy Insights
        • Opportunity: A New Agent with Increased Efficacy Based on a Higher Patient Responder Rate
        • Opportunity: A New Agent with Greater Tolerability due to a Reduced Risk of Gastrointestinal Side Effects
        • Opportunity: A Novel Non-Oral Agent with Equivalent Efficacy
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content. Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.